<DOC>
	<DOCNO>NCT00281736</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use drug , HPPH , absorb tumor cell . The drug become active expose light , kill tumor cell . HPPH may effective kill precancerous cell tumor cell . PURPOSE : This randomized phase II trial study well photodynamic therapy HPPH work treat patient precancerous esophageal condition stage 0 stage I esophageal cancer .</brief_summary>
	<brief_title>Photodynamic Therapy Treating Patients With Precancerous Esophageal Conditions Early Stage Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response patient high-grade dysplasia , carcinoma situ , early intramucosal adenocarcinoma esophagus Barrett 's esophagus treat photodynamic therapy use HPPH . - Determine safety , term toxicity surround normal tissue , regimen patient . - Determine toxic effect regimen surround normal tissue patient . - Determine incidence adenocarcinoma patient treatment . - Determine magnitude duration increase skin sun sensitivity patient treat regimen . - Determine minimal erythemal dose regimen patient . OUTLINE : This randomize study . Patients stratify accord presence intramucosal tumor ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive HPPH IV 1 hour day 1 . Approximately 24 hour later , lesion expose laser light endoscopically . - Arm II : Patients receive HPPH arm I , high dose , follow laser light exposure . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 60 patient ( 30 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm highgrade dysplasia , carcinoma situ , early intramucosal adenocarcinoma esophagus Stage 0 N0 , M0 primary recurrent disease Diagnosis Barrett 's esophagus Ineligible refuse surgical resection Requires endoscopy PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 50100 % Life expectancy Not specify Hematopoietic WBC ≥ 4,000/mm^3 Platelet count ≥ 100,000/mm^3 PT ≤ 1.5 time upper limit normal ( ULN ) Hepatic Bilirubin ≤ 2.0 mg/dL Alkaline phosphatase ≤ 3 time ULN ALT ≤ 3 time ULN Renal Creatinine ≤ 2 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No contraindication endoscopy No malignancy except nonmelanoma skin cancer another cancer patient deem diseasefree No porphyria hypersensitivity porphyrin porphyrinlike compound PRIOR CONCURRENT THERAPY : Chemotherapy At least 1 month since prior chemotherapy No concurrent chemotherapy Radiotherapy At least 1 month since prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Other At least 1 month since prior NdYAG laser therapy At least 4 week since prior therapy disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage 0 esophageal cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>precancerous condition</keyword>
</DOC>